ABSTRACT BACKGROUND: The present study was designed to compare the effectiveness of topical silver sulfadiazine (SSD) and Ankaferd Blood Stopper ® (ABS) usage in experimental partial-thickness burns in rats.
worldwide. [2] In addition to its effectiveness, SSD cream has some important systemic complications, such as neutropenia, erythema multiforme, methemoglobinemia, and crystalluria. [3] Ankaferd Blood Stopper (ABS) (İmmun İlaç Kozmetik Ltd., Istanbul, Turkey) is a traditional and unique medicinal plant extract that has historically been used in Turkey as a hemostatic agent. [4] The promising result of ABS in promoting tissue healing has been shown in several studies recently. [5] Thus, the aim of the experimental study was to compare the effectiveness of topical ABS and SSD in partial-thickness burns in rats.
MATERIALS AND METHODS
After obtaining permission from the ethical board of our uni-
EXPERIMENTAL STUDY INTRODUCTION
Burn injuries, an important global public health issue, are still considered to be among the most destructive of all types of injuries. The main goal of the treatment of burns is a fast epithelization and wound healing to prevent secondary infections, as well as to reduce the functional and aesthetic issues. On the other hand, the likelihood of occurrence of deformities, mis-formation, and infection at the burn site of the wound are the main concerns toward their implementation. [1] Topical agents may decrease the morbidity and mortality rates by preventing sepsis and bacterial contamination during the healing process of the burn wounds. Currently, in severe burns, silver sulfadiazine (SSD) as a topical agent is used versity, the study was designed according to the Health Guide for the Care and Use of Laboratory Animals by the National Institutes of Health (NIH publication no.: 86-23, revised 1985, Bethesda) criteria. The study was completed at the Experimental Research Center of Necmettin Erbakan University. A total of 21 male Wistar albino rats weighing 250-290 (range: 270±19) g were used for the study. The rats were kept at an equal hour light and dark cycle at a temperature of 22 °C-26 °C. They were given a standard rat diet. By means of drinking water, 100 mg/5 mL ibuprofen was administered as an analgesic after the burn formation. The rats were set up individually and approached with appropriate equipment to prevent contamination.
Anesthesia was administered by a single dose of 50 mg/kg ketamine hydrochloride (Ketalar 50 mg/mL; Parke-Davis, MI, USA) and 6 mg/kg intramuscular xylazine hydrochloride (Rompun 23.32 mg/mL; Bayer, Leverkusen, Germany). The back region of the rats was shaved and cleaned with a 10% povidone-iodine solution (Kim-Pa, Poviiodeks, 10% povidone-iodine). A specifically designed round brass probe (3×3 cm diameter) was used to induce the burns (Fig. 1) . After sterilization in boiling water for 5 min, the probe was applied with no pressure to the skin of anesthetized rats for 15 s. With this procedure, second-degree partial-thickness burns were formed. After the burns were formed, all the rats were placed and kept in individual cages and divided into three groups. Ankaferd Blood Stopper ® pad was used in Group 1 (ABS group), silver sulfadiazine (Silverdin ® ; Toprak Drug Co., Turkey) 1% in Group 2 (SSD group), and isotonic saline solution-impregnated pads in Group 3 (Control group). The healing period was observed clinically and histopathologically.
To specify the wound healing process, two parameters were used as follows: 1. the exact day on which 50% and 80% of re-epithelization were detected at first 2. histopathological changes.
The study period did not end until 4 weeks after the burns were observed. Digital photos of the burns were taken with a camera every day 3 of the follow-up. On week 4 of the follow-up period, for histological evaluation, skin samples were obtained at the same distance and under the same conditions. The healing process of the burns was evaluated by the same clinician who is experienced on burn and blinded to the study. The measurements of the burn areas were evaluated using the NIH ImageJ program as described in our previous study. [6] The percentage of re-epithelization was calculated as follows:
Percentage of re-epithelization=first burn area-current burn area/first burn area.
The 50% and 80% of re-epithelization rates were recorded precisely until the end of the study. All the rats were sacrificed after the photos were taken on week 4 of the study. The resected full-thickness skin samples were collected from the burn areas. Histological parameters (epithelialization, polymorphonuclear neutrophil (PMN), angiogenesis, and fibrosis) were evaluated on biopsy specimens of the wounds at the end of the study as follows: for fibrosis (collagen bundles): normal bundle: 2, disorganized/edematous: 1, and amorphous: 0 and for PMN: 40× field: 0-10: 2, 11-40: 1, and >40: 0. 
RESULTS
The mean times for 50% of re-epithelization at first were 10.8 days, 13.8 days, and 16.8 days in the ABS group, SSD group, and control group, respectively (p<0.001) (Fig. 2) , and for 80% of re-epithelization at first were 16.4 days, 19.7 days, and 25.2 days, respectively (p<0.001) (Fig. 3 ). The ABS group had faster healing duration than the other groups with respect to 50% and 80% of re-epithelization (Fig. 4) . These differences were statistically significant. The SSD group had also better healing rates than the control group based on 50% and 80% of re-epithelization of the burn. The mean inflammatory scores revealed a significant difference in the ABS group compared with the others (p<0.05). The collagen scores were also higher in the ABS group than in the other groups (Table  1 ) (p<0.05) (Fig. 5a-c) .
DISCUSSION
The overall process of burn healing is similar with that seen in the wound healing process which generally follows the phases of inflammation, proliferation, and remodeling. This healing process can be obstructed due to many reasons. Miscellaneous studies have shown that infection not only is the main cause for the failure of healing but also can increase the risk of mortality among burn patients. [7] Thus far, many investiga- 
(a) (b) (c)
tions have been conducted to understand how to prevent secondary infection and to accelerate the healing process. Usage of topical antibiotics has already been determined as effective in preventing mortality. [8] SSD, one of the popular topical antibiotics, is convenient widely and easy to use, gives no pain, and has low toxicity while showing a good antibacterial effect. Therefore, SSD is the gold standard as an antimicrobial topical ointment in burn patients now. [9] In addition to its antimicrobial effect, SSD has a positive effect on the proliferation of fibroblasts producing collagen and fibronectin and stimulates the production of growth factor and cytokines from cells, such as macrophages during the wound healing process. [10] However, there are some side effects of SSD, such as neutropenia, erythema multiforme, crystalluria, and methemoglobinemia, and can delay the wound healing process. [3] On the other hand, the healing of the burn wound is still controversial. There are only a few drugs ruling the physiological wound healing defined to be effective. [11] In the past few years, the effect of some herbal medicine on burn wounds has been investigated widely, and several products derived from plants have been shown to have strong wound healing effects. [11] While most of the medicines are a mixture of several plants, none of these traditional ointments were studied prominently. In the present study, ABS was compared with SSD as a standard treatment for burns in rats.
ABS, a unique traditional herbal medicine that has been consumed for many years in Anatolia as a hemostatic agent, was certified by the Turkish Ministry of Health in October 2007. [12] ABS is a standardized mixture of the plants Alpinia officinarum, Thymus vulgaris, Vitis vinifera, Urtica dioica, and Glycyrrhiza glabra. Each of these plants ABS consumes has some various beneficial effect on blood cells, endothelium, cellular proliferation, angiogenesis, cell mediators, and/or vascular dynamics. [13] In addition to its hemostatic activity, ABS may also prevent bacterial growth. [14] In a previous study, the antimicrobial activity of ABS was tested against 102 clinical isolates, which reported that ABS was active against all of these isolates, and the zones of inhibition were within a range of 8-10 mm diameter. [15] The antibacterial efficiency of ABS toward Gram-negative and Gram-positive food, as well as human pathogens, has also been determined. [14] Neither systemic nor local adverse effects and/or toxicity have been seen in association with anecdotal and experimental topical uses of ABS. Hematotoxicity, acute mucosal toxicity, nephrotoxicity, hepatotoxicity, and biochemical toxicity have not also been defined during the short-term follow-up of animals. [14] The comparison between the groups in our study showed that ABS was statistically significantly superior with respect to histopathological evaluation and recovery duration compared with the previously proven SSD. Kaya et al. [16] and Topal et al. [17] have previously demonstrated that even though the ABS and control groups are similar with respect to wound healing on day 7, ABS is statistically superior on day 14. In contrast, Topal et al. [17] could not determine any difference between ABS and SSD in burn wounds. On the other hand, in our study, ABS had a shorter recovery time than SSD based on 50% and 80% of re-epithelization rates. In our opinion, ABS may have a superior beneficial effect and can be widely used in the treatments of burn injuries, instead of SSD usage. 
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